Jurnal Penelitian Kesehatan
Vol 14, No 2 (2023): April 2023

EQ-5D-5L untuk Pengukuran Biaya dan Indeks Utilitas pada Pasien Gagal Ginjal Kronik dengan Hemodialisis

Clara Ritawany Sinaga (Fakultas Farmasi, Universitas Setia Budi Surakarta / STIKES Dirgahayu Samarinda, Samarinda
clarasinaga24@gmail.com (koresponden))

Gunawan Pamudji Widodo (Fakultas Farmasi, Universitas Setia Budi Surakarta)
Tri Murti Andayani (Fakultas Farmasi, Universitas Gadjah Mada, Yogyakarta)



Article Info

Publish Date
30 Apr 2023

Abstract

Treatment of chronic kidney failure requires a large amount of money, especially if the patient has complications, so cost analysis and utility index measurements are needed. This study aimed to determine the effect of complications on cost and utility index in patients with chronic kidney failure on hemodialysis. This research was an observational study that applied a cross-sectional design from the perspective of the service provider. The subjects of the study were 76 outpatients with chronic kidney failure who underwent hemodialysis at the Hemodialysis Unit at the Abdoel Wahab Sjahranie Regional General Hospital, Samarinda from October to November 2020. Complication data were obtained from medical records, financing data were obtained from the finance department, and data on complications the utility index were obtained through direct interviews with patients using the EQ-5D-5L questionnaire. Data were analyzed using the Kruskal-Wallis test. The results of the research showed that the real cost for one month was Rp. 972,540,696 with an average cost of Rp. 12,796,588±120,241. Meanwhile, the real cost per episode of hemodialysis was Rp. 119,582,312 with an average cost of IDR 1,573,451 ± 77,506. The patient utility index was 0.645±0.210. The p-value for the impact of complications on the utility index was 0.012 (<0.05), while the p-value for the impact of complications on costs was 0.095 (>0.05). Thus it could be concluded that complications in chronic renal failure patients had an impact on the utility index.Keywords: chronic kidney failure; hemodialysis; complications; utility index ABSTRAK Penanganan gagal ginjal kronis membutuhkan biaya yang besar, terutama apabila pasien mengalami komplikasi, sehingga diperlukan analisis biaya dan pengukuran indeks utilitas. Penelitian ini bertujuan untuk mengetahui pengaruh komplikasi terhadap biaya dan indeks utilitas pada pasien dengan gagal ginjal kronis dengan hemodialisis. Penelitian ini merupakan studi observasional yang menerapkan rancangan cross-sectional menurut perspektif pemberi layanan. Subyek penelitian adalah 76 pasien rawat jalan dengan gagal ginjal kronis yang menjalani hemodialisis di Unit Hemodialisis Rumah Sakit Umum Daerah Abdoel Wahab Sjahranie, Samarinda pada bulan Oktober sampai November 2020. Data komplikasi diperoleh dari rekam medik, data pembiayaan di peroleh dari bagian keuangan, dan data indeks utilitas diperoleh melalui wawancara secara langsung dengan pasien menggunakan kuesioner EQ-5D-5L. Data dianalisis menggunakan uji Kruskal-Wallis. Hasil penelitian menunjukkan bahwa biaya riil selama satu bulan adalah Rp. 972.540.696 dengan biaya rata-rata Rp. 12.796.588±120.241. Sedangkan biaya riil per episode hemodialisis adalah Rp. 119.582.312 dengan biaya rata-rata Rp.1.573.451±77.506. Indeks utilitas pasien adalah 0,645±0,210. Nilai p untuk dampak komplikasi terhadap indeks utilitas adalah 0,012 (<0,05), sedangkan nilai p untuk dampak komplikasi terhadap biaya adalah 0,095 (>0,05). Dengan demikian bisa disimpulkan bahwa komplikasi pada pasien gagal ginjal kronis berdampak pada indeks utilitas.Kata kunci: gagal ginjal kronis; hemodialisis; komplikasi; indeks utilitas 

Copyrights © 2023






Journal Info

Abbrev

sf

Publisher

Subject

Health Professions Medicine & Pharmacology Nursing Public Health

Description

Journal of Health Research "Forikes Voice" is a medium for the publication of articles on research and review of the literature. We accept articles in the areas of health such as public health, medicine, nursing, midwifery, nutrition, pharmaceutical, environmental health, health technology, clinical ...